Nitrogen Containing Patents (Class 514/459)
  • Patent number: 10596106
    Abstract: Systems and methods for removal of human cerumen are provided. A composition for removal of cerumen includes at least one cerumenolytically acceptable active agent and an otologically acceptable vehicle. The cerumenolytically acceptable active agent may be an alpha-hydroxy acid (AHA). Exemplary AHA may include, but are not limited to, glycolic acid, tartronic acid, lactic acid, malic acid and any derivative or mixture thereof. The otologically acceptable vehicle may be sodium or potassium salts of bicarbonate aqueous buffer. Yet further, the otologically acceptable vehicle may contain sodium docusate. Cerumen may be removed and/or a cerumen impaction may be treated by administering to a patient in need thereof a composition comprising an AHA and an otologically acceptable vehicle.
    Type: Grant
    Filed: August 9, 2017
    Date of Patent: March 24, 2020
    Assignee: Eosera, Inc.
    Inventors: Joe Griffin, Eric Anderson
  • Patent number: 10448632
    Abstract: The present invention provides methods of regulating plant stress tolerance.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: October 22, 2019
    Assignee: The Regents of the University of California
    Inventors: Sean R. Cutler, Andrew Defries
  • Patent number: 10385400
    Abstract: A method of evaluating a cancer cell sample, the method comprising: a. obtaining a cancer cell sample, optionally a breast cancer cell sample or an ovarian cancer cell sample, after the cancer cells have been exposed to a radiation dose; b. assaying the cancer cell sample to obtain a RNA integrity value and/or a RNA concentration of the cancer cell sample.
    Type: Grant
    Filed: December 3, 2013
    Date of Patent: August 20, 2019
    Assignee: RNA DIAGNOSTICS INC.
    Inventors: Mu Zhu, Amadeo Mark Parissenti, Laura Pritzker, Kenneth Pritzker, Stacey Santi, Baoqing Guo, Xiaohui Wang, Rashmi Narendrula
  • Patent number: 10246819
    Abstract: A composition, method and kit for producing reversibly dyed soft contact lenses is disclosed. The contact lenses are submerged in saline solution and a dye is added to the saline solution, either directly or by means of a strip that has been impregnated with the dye. After a period of time, the lens absorbs the dye and can be removed from the solution and placed on the eye. Once the lens is illuminated with ultraviolet light, it will glow or fluoresce. An eye having the soft contact lens applied to a cornea thereof is examined under a luminescent radiation stored in the soft contact lens. The dyeing method does not utilize heat and thus is reversible. Soaking the lens in additional saline solution for a period of time will cause the dye to return to its non-dyed state. A stabilizing compound and a method of stabilization are also disclosed herein.
    Type: Grant
    Filed: November 10, 2017
    Date of Patent: April 2, 2019
    Inventor: Michael D. Conte
  • Patent number: 9980936
    Abstract: The disclosure relates to BH4 inhibitors and therapeutic uses relates thereto. In certain embodiments, the disclosure relates to methods of treating or preventing cancer, such as lung cancer, comprising administering therapeutically effective amount of a pharmaceutical composition comprising a compound disclosed herein or pharmaceutically acceptable salt to a subject in need thereof.
    Type: Grant
    Filed: May 5, 2015
    Date of Patent: May 29, 2018
    Assignees: Emory University, The Board of Regents of the University of Texas System
    Inventors: Xingming Deng, Jia Zhou, Chunyong Ding
  • Patent number: 9949945
    Abstract: Equatorial 2,3-fluorinated glycosides compounds of formula (I) useful for the treatment or prophylaxis of viral infection, particularly viral influenza, the methods for their preparation, and their pharmaceutical compositions are provided. The therapeutic effect is achieved via inhibition of viral neuraminidases.
    Type: Grant
    Filed: August 22, 2016
    Date of Patent: April 24, 2018
    Assignee: The University of British Columbia
    Inventors: Stephen Withers, Hongming Chen, Ricardo Resende, Jennifer Lois Breschkin
  • Patent number: 9840513
    Abstract: The present invention provides for compounds of formula (I) wherein X, Y, and R1 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sjögren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).
    Type: Grant
    Filed: July 8, 2016
    Date of Patent: December 12, 2017
    Assignees: AbbVie S.á.r.l., Galapagos NV
    Inventors: Robert J. Altenbach, Andrew Bogdan, Marlon D. Cowart, William Ramesh Esmieu, Gregory A. Gfesser, Stephen N. Greszler, John R. Koenig, Philip R. Kym, Bo Liu, Karine Fabienne Malagu, Sachin V. Patel, Marc J. Scanio, Xenia B. Searle, Eric Voight, Xeuquing Wang, Ming C. Yeung
  • Patent number: 9765106
    Abstract: N. gonorrhoeae has become resistant to almost every conventional antibiotic. Described herein is the use of CMP-nonulosonate analogs to counter gonococcal complement evasion. The nonulosonate sugar is incorporated into the lipooligosaccharide of the N. gonorrhoeae which in turn reduces the serum resistance of the bacteria. This provides a novel therapeutic strategy against the global threat of multi-drug resistant gonorrhea.
    Type: Grant
    Filed: February 20, 2015
    Date of Patent: September 19, 2017
    Assignee: National Research Council of Canada
    Inventors: Ian Schoenhofen, Dennis M. Whitfield, Sanjay Ram
  • Patent number: 9763903
    Abstract: The present invention provides methods, compositions, and kits for treating intestinal hyperpermeability in a subject in need thereof, including conditions such as hyperglycemia and underlying diseases such as diabetes, autism, fibromyalgia, inflammatory bowel disease (IBD), graft versus host disease (GVHD), HIV/AIDS, multiple organ dysfunction syndrome, irritable bowel syndrome (IBS), celiac disease, eczema, psoriasis, acute pancreatitis, Parkinson's disease, depression, chronic fatigue syndrome, asthma, multiple sclerosis, arthritis, ankylosing spondylitis, nonalcoholic fatty liver disease, alcoholic cirrhosis, environmental enteropathy, or kwashiorkor.
    Type: Grant
    Filed: March 3, 2016
    Date of Patent: September 19, 2017
    Inventor: Steven Hoffman
  • Patent number: 9693994
    Abstract: In some aspects, methods for treating a bacterial infection in a mammalian subject are provided. In some embodiments, a class IIa HDAC inhibitor such as, e.g., a HDAC4 inhibitor, may be used to treat a bacterial infection such as, e.g., anthrax, pertussis, tuberculosis, or cholera.
    Type: Grant
    Filed: April 9, 2015
    Date of Patent: July 4, 2017
    Assignee: Research Development Foundation
    Inventor: Marc Montminy
  • Patent number: 9637465
    Abstract: Equatorial 2,3-fluorinated glycosides compounds of formula (I) useful for the treatment or prophylaxis of viral infection, particularly viral influenza, the methods for their preparation, and their pharmaceutical compositions. The therapeutic effect is achieved via inhibition of viral neuraminidases.
    Type: Grant
    Filed: January 17, 2013
    Date of Patent: May 2, 2017
    Assignee: The University of British Columbia
    Inventors: Stephen Withers, Hongming Chen, Ricardo Resende, Jennifer Lois Breschkin
  • Patent number: 9221859
    Abstract: Compounds having a structure of Formula I and compositions comprising these compounds are provided. Uses of such compounds and compositions are provided for treatment or prophylaxis of viral infection. In particular, compounds and compositions may be for use in the treatment or prophylaxis of viral influenza.
    Type: Grant
    Filed: July 14, 2014
    Date of Patent: December 29, 2015
    Assignee: The University of British Columbia
    Inventors: Stephen Withers, Andrew Graham Watts, Jin Hyo Kim, Tom Wennekes
  • Patent number: 9187445
    Abstract: A compound of general formula (I) wherein A, Y, W, R1, R2, R3, R4, R5, and R6 take various meanings for use in the treatment of cancer.
    Type: Grant
    Filed: December 19, 2008
    Date of Patent: November 17, 2015
    Assignee: PHARMA MAR, S.A.
    Inventors: Alberto Rodríguez Vicente, María Garranzo García-Ibarrola, Carmen Murcia Pérez, Francisco Sánchez Sancho, María del Carmen Cuevas Marchante, Cristina Mateo Urbano, Isabel Digón Juárez
  • Patent number: 9132126
    Abstract: Disclosed are a phenyl-isoxazol derivative compound, which is useful as a treatment material for virus infection, especially, infection of an influenza virus, or its pharmaceutically acceptable derivative, a preparation method thereof, and an illness treatment pharmaceutical composition including the compound as an active ingredient.
    Type: Grant
    Filed: March 30, 2012
    Date of Patent: September 15, 2015
    Assignee: IL-YANG PHARM. CO., LTD.
    Inventors: Dong Yeon Kim, Dae Jin Cho, Gong Yeal Lee, Hong Youb Kim, Seok Hun Woo, Hae Un Lee, Sung Moo Kim, Choong Am Ahn, Seung Bin Yoon
  • Publication number: 20150148347
    Abstract: A compound of formula I, wherein the groups R1, R2, R3, X, m, and n are defined as in claim 1, which have valuable pharmacological properties, in particular bind to the GPR40 receptor and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2. Furthermore, the invention relates to novel intermediates, useful for the synthesis of compounds of formula I.
    Type: Application
    Filed: November 25, 2014
    Publication date: May 28, 2015
    Inventors: Iain LINGARD, Dieter HAMPRECHT
  • Publication number: 20150141465
    Abstract: Provide herein are compounds and pharmaceutical compositions suitable as modulators of hemoglobin, methods and intermediates for their preparation, and methods for their use in treating disorders mediated by hemoglobin and disorders that would benefit from tissue and/or cellular oxygenation.
    Type: Application
    Filed: November 14, 2014
    Publication date: May 21, 2015
    Inventors: Calvin W. YEE, Zhe Li
  • Patent number: 9034920
    Abstract: Fluorescent polymeric materials are disclosed comprising a polymer and one or more lipid soluble rhodamine dyes with the following core structure: The materials are especially useful in the preparation of multicolored microparticles, especially multicolored polystyrene microparticles, for use in the multiplexed analysis of a plurality of analytes in a single sample. When excited by a light source, the materials give off a unique emission based on the nature, concentration and ratio of the dyes therein. Methods of preparing and using the fluorescent polymeric materials are also disclosed.
    Type: Grant
    Filed: November 26, 2013
    Date of Patent: May 19, 2015
    Assignee: Applied Biosystems, LLC
    Inventors: Joe Y. L. Lam, Steven Menchen, Ruiming Zou, Scott Benson
  • Patent number: 9029413
    Abstract: Alterations of certain metabolite concentrations and fluxes that occur in response to viral infection are described. Host cell enzymes in the involved metabolic pathways are selected as targets for intervention; i.e., to restore metabolic flux to disadvantage viral replication, or to further derange metabolic flux resulting in “suicide” of viral-infected cells (but not uninfected cells) to limit viral propagation. While any of the enzymes in the relevant metabolic pathway can be selected, pivotal enzymes at key control points in these metabolic pathways are preferred as candidate antiviral drug targets. Inhibitors of these enzymes are used to reverse, or redirect, the effects of the viral infection. Drug candidates are tested for antiviral activity using screening assays in vitro and host cells, and in animal models. Animal models are then used to test efficacy of candidate compounds in preventing and treating viral infections. Antiviral activity of enzyme inhibitors is demonstrated.
    Type: Grant
    Filed: April 3, 2012
    Date of Patent: May 12, 2015
    Assignee: The Trustees of Princeton University
    Inventors: Josh Munger, Bryson Bennett, Thomas Shenk, Joshua Rabinowitz
  • Patent number: 9018222
    Abstract: The present invention refers to the use of sodium channel blockers such as tetrodotoxin or saxitoxin, its analogues/derivatives as well as their acceptable salts, for the production of a medicament for the treatment of neuropathic pain resulting from chemotherapy.
    Type: Grant
    Filed: March 26, 2007
    Date of Patent: April 28, 2015
    Assignee: Wex Medical Limited
    Inventors: Helmut Heinrich Buschmann, Jose Miguel Vela Hernandez, Jose Manuel Baeyens
  • Publication number: 20150094285
    Abstract: A composition (e.g., phytochemical composition) including sesamin, the composition exhibiting anti-inflammatory, anti-cytokine storm, connective tissue preservation, anti-viral, and/or other properties in biological tissue. The phytochemical composition therapeutically affects a pro-inflammatory cytokine condition, for instance facilitating or effectuating decrease in a quantity of a pro-inflammatory cytokine, for example, interleukin-1 and tumor necrosis-alpha. The phytochemical composition facilitates or effectuates an increase in quantity of an anti-inflammatory cytokines. The phytochemical composition can additionally facilitate a connective tissue extracellular matrix (ECM) preservation effect. The phytochemical composition can also inhibit an action of a viral neuraminidase, for example, the influenza A virus neuraminidase.
    Type: Application
    Filed: December 5, 2014
    Publication date: April 2, 2015
    Applicants: COMMISSION ON HIGHER EDUCATION, CHIANG MAI UNIVERSITY
    Inventor: Prachya KONGTAWELERT
  • Publication number: 20150087675
    Abstract: Disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds corresponding to general formula (I) are disclosed. Also disclosed, are pharmaceutical compositions including these compounds and methods of using these compounds and compositions for the treatment of chemokine-mediated diseases.
    Type: Application
    Filed: October 26, 2012
    Publication date: March 26, 2015
    Applicant: GLADERMA RESEARCH & DEVELOPMENT
    Inventors: Branislav Musicki, Jerôme Aubert, Patricia Rossio, Marlène Schuppli-Nollet, Laurence Clary, Jean-Guy Boiteau
  • Publication number: 20150080369
    Abstract: The present invention is directed to novel retinoid-related orphan receptor gamma (ROR?) modulators, processes for their preparation, pharmaceutical compositions containing these modulators, and their use in the treatment of inflammatory, metabolic and autoimmune diseases mediated by ROR?.
    Type: Application
    Filed: April 25, 2013
    Publication date: March 19, 2015
    Inventors: Veronique Birault, Amanda Jennifer Campbell, Stephen Harrison, Joelle Le, Lena Shukla
  • Publication number: 20150079035
    Abstract: The present invention provides, inter alia, a compound having the structure: (Formula (I). Also provided are compositions containing a pharmaceutically acceptable carrier and a compound according to the present invention. Further provided are methods for treating or ameliorating the effects of an excitotoxic disorder in a subject, methods of modulating ferroptosis in a subject, methods of reducing reactive oxygen species (ROS) in a cell, and methods for treating or ameliorating the effects of a neurodegenerative disease.
    Type: Application
    Filed: April 2, 2013
    Publication date: March 19, 2015
    Inventors: Brent R. Stockwell, Scott J. Dixon, Rachid Skouta
  • Patent number: 8980944
    Abstract: The present invention is directed to the use of EP2 and/or EP4 agonists as therapeutics for the treatment of diseases associated with influenza A viruses, such as for example H5N1 and mutations thereof.
    Type: Grant
    Filed: March 28, 2011
    Date of Patent: March 17, 2015
    Assignee: Gemmus Pharma Inc.
    Inventors: Daryl Faulds, William J. Guilford, Wolfgang Seifert
  • Publication number: 20150064282
    Abstract: Use of Neul sialidase inhibitors for the treatment of cancer as a monotherapy or in combination with known chemotherapeutics. Preferably, Neul sialidase inhibitors are oseltamivir phosphate or 2-deoxy-2,3-dehydro-N-acetylneuraminic acid (DANA) or analogues thereof.
    Type: Application
    Filed: November 4, 2011
    Publication date: March 5, 2015
    Inventors: Paul Zachary Josefowitz, Myron R. Szewczuk
  • Patent number: 8969340
    Abstract: The present invention provides methods and compositions for treating chronic pelvic pain syndrome. In particular, the present invention provides methods and compositions for treating chronic pelvic pain syndrome with an agent that targets MCP-1, MIP-1?, or the CCR-2 receptor.
    Type: Grant
    Filed: July 8, 2013
    Date of Patent: March 3, 2015
    Assignee: Northwestern University
    Inventors: Anthony J. Schaeffer, David Klumpp, Praveen Thumbikat
  • Publication number: 20150056163
    Abstract: The present invention relates to methods for preventing or treating Human Immunodeficiency Virus (HIV) infection, inflammatory conditions, and graft-versus-host-disease (GVHD) in a subject. Therapeutic compositions of the present invention comprise Leukocidin E (LukE) and/or D proteins or polypeptides. The invention further relates to methods of treating Staphylococcus aureus infection by administering a composition comprising a CCR5 antagonist or any molecule that blocks LukE/D interaction with CCR5+ cells in an amount effective to treat the S. aureus infection in the subject.
    Type: Application
    Filed: August 25, 2014
    Publication date: February 26, 2015
    Inventors: Victor J. Torres, Derya Unutmaz, Francis Alonzo, III
  • Publication number: 20150051275
    Abstract: The invention provides compounds of Formula I: and pharmaceutically acceptable salts thereof, wherein R1, R2, R3 R4, R5, and G are as described in the specification, as well compositions comprising a compound of formula I, methods of making such compounds, and methods of using such compounds, e.g., as inhibitors of bacterial RNA polymerase and as antibacterial agents.
    Type: Application
    Filed: March 22, 2013
    Publication date: February 19, 2015
    Inventors: Richard H. Ebright, Yon W. Ebright
  • Publication number: 20150051144
    Abstract: The present invention relates to compounds of the general formula (I), their tautomeric forms, their stereoisomers, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, methods for their preparation, use of these compounds in medicine and the intermediates involved in their preparation. The present invention is directed towards compounds which can be used to treat diseases such as hyperlipidemia and also have a beneficial effect on cholesterol.
    Type: Application
    Filed: September 26, 2012
    Publication date: February 19, 2015
    Inventors: Harikishore Pingali, Vrajesh Pandya
  • Publication number: 20150045409
    Abstract: An amide compound represented by formula (I) has an excellent pest control effect. (In the formula, Y represents a 3-7 membered saturated heterocyclic ring which contains, as ring-forming components(s), one or more atoms or groups that are selected from the group consisting of an oxygen atom and —S(O)t—, the saturated heterocyclic ring may have one to three atoms or groups selected from group D and t represents 0 or the like; X represents a C1-C10 chain hydrocarbon group which may have one or more atoms or groups that are selected from group A, or the like; W represents —CR8— or the like; r represents 1 or the like; R1, R2, R3, R4, R5, R6, R7 and R8 may be the same or different and each represents a hydrogen atom or the like; and n represents 1 or the like.
    Type: Application
    Filed: February 5, 2013
    Publication date: February 12, 2015
    Inventors: Hideki Ihara, Tomotsugu Awano, Jun Ohshita, Noritada Matsuo
  • Patent number: 8952183
    Abstract: The present invention describes compounds of Formula I or a pharmaceutically acceptable salts or derivatives thereof. Compositions comprising compounds of Formula I are also described. The present invention further relates to a method of producing non-2-enonate compounds.
    Type: Grant
    Filed: May 4, 2010
    Date of Patent: February 10, 2015
    Assignee: National Research Council of Canada
    Inventors: Ian C. Schoenhofen, Dennis M. Whitfield, Susan M. Logan
  • Patent number: 8951999
    Abstract: This invention relates to compounds of formula I, their use as inhibitors of the microsomal prostaglandin E2 synthase-1 (mPGES-1), pharmaceutical compositions containing them, and their use as medicaments for the treatment and/or prevention of inflammatory diseases and associated conditions such as inflammatory/nociceptive pain. A, M, R1, R2, R7, Ra, Rb, Q3, Q4, Q6, Z2, Z4, Z5, Z6 and W have meanings given in the description.
    Type: Grant
    Filed: October 20, 2010
    Date of Patent: February 10, 2015
    Assignee: Orexo AB
    Inventors: Henning Priepke, Henri Doods, Raimund Kuelzer, Roland Pfau, Dirk Stenkamp, Robert Roenn, Benjamin Pelcman
  • Patent number: 8946295
    Abstract: A method for promoting wound healing and preventing scar formation in a variety of wounds in skin, mucosa, and cornea. The method comprises administering a therapeutically effective amount of a histone deacetylase inhibitor or a hyperacetylating agent. The histone deacetylase inhibitor or hyperacetylating agent is capable of stimulating multiple cytokines/growth factors in the early phase of wound healing, and suppressing fibrogenic cytokines/growth factors in the late phase of tissue remodeling in the wound site, and is useful in promoting epithelial cell re-growth and reducing excessive collagen accumulation, which results in rapid wound closure with reduced scaring.
    Type: Grant
    Filed: May 10, 2004
    Date of Patent: February 3, 2015
    Assignee: Sunny Pharmtech Inc.
    Inventor: Yih-Lin Chung
  • Publication number: 20150025110
    Abstract: This invention relates to novel 1-cycloalkyl- or 1-heterocyclyl-hydroxyimino-3-phenyl-propanes of the formula wherein R1 to R7 are as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds are GPBAR1 agonists and may therefore be useful as medicaments for the treatment of diseases such as type II diabetes.
    Type: Application
    Filed: October 9, 2014
    Publication date: January 22, 2015
    Inventors: Henrietta Dehmlow, Rainer E. Martin, Patrizio Mattei, Ulrike Obst Sander, Hans Richter
  • Publication number: 20150005348
    Abstract: An amide compound represented by formula (I) has an excellent pest control effect. (In the formula, Y represents a 3-7 membered saturated heterocyclic ring which contains, as ring-forming components(s), one or more atoms or groups that are selected from the group consisting of an oxygen atom and —S(O)t—, the saturated heterocyclic ring may have one to three atoms or groups selected from group D and t represents 0 or the like; x represents a C1-C8 chain hydrocarbon group having one group that is selected from group A; W represents —CR8— or the like; r represents 1 or the like; R1, R2, R3, R4, R5, R6, R7 and R8 may be the same or different and each represents a hydrogen atom or the like; and n represents 1 or the like.
    Type: Application
    Filed: February 5, 2013
    Publication date: January 1, 2015
    Inventors: Jun Ohshita, Tomotsugu Awano, Hideki Ihara
  • Publication number: 20140378540
    Abstract: The present invention relates to novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The invention also relates to the processes for the synthesis of novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The present invention also provides pharmaceutical compositions comprising novel compounds of Formula I and methods of treating or preventing one or more conditions or diseases that may be regulated or normalized via inhibition of Sodium Glucose Cotransporter-2 (SGLT-2).
    Type: Application
    Filed: September 12, 2012
    Publication date: December 25, 2014
    Inventors: Rajesh Jain, Sanjay Trehan, Jagattaran Das, Gurmeet Kaur Nanda, Sastry V. R. S Thungathurthi, Nishan Singh, Sudhir Kumar Sharma
  • Publication number: 20140350095
    Abstract: Equatorial 2,3-fluorinated glycosides compounds of formula (I) useful for the treatment or prophylaxis of viral infection, particularly viral influenza, the methods for their preparation, and their pharmaceutical compositions. The therapeutic effect is achieved via inhibition of viral neuraminidases.
    Type: Application
    Filed: January 17, 2013
    Publication date: November 27, 2014
    Inventors: Stephen Withers, Hongming Chen, Ricardo Resende, Jennifer Lois Breschkin
  • Publication number: 20140342999
    Abstract: Disclosed are compounds and methods of using compounds of the invention for treating a subject with a proliferative disorder, such as cancer, and methods for treating disorders responsive to Hsp70 induction and/or natural killer induction. Also, disclosed are pharmaceutical compositions comprising compounds of the invention and a pharmaceutically acceptable carrier.
    Type: Application
    Filed: May 19, 2014
    Publication date: November 20, 2014
    Applicant: SYNTA PHARMACEUTICALS CORP.
    Inventors: Lijun Sun, Jun Jiang
  • Publication number: 20140336137
    Abstract: The invention relates to nitroso derivatives including carboxylic acid and phosphoric acid esters of hydroxy nitroso compounds that donate nitroxyl (HNO) under physiological conditions. The compounds and compositions of the invention are useful in treating and/or preventing the onset and/or development of diseases or conditions that are responsive to nitroxyl therapy, including heart failure, ischemia/reperfusion injury and cancer.
    Type: Application
    Filed: July 28, 2014
    Publication date: November 13, 2014
    Inventors: Lisa Marie Frost, Stephen Martin Courtney, Frederick Arthur Brookfield, Vincent Jacob Kalish
  • Publication number: 20140323530
    Abstract: Provided are amine derivative compounds, pharmaceutical compositions thereof, and methods of treating ophthalmic diseases and disorders, such as age-related macular degeneration and Stargardt's Disease, using said compounds and compositions.
    Type: Application
    Filed: March 26, 2014
    Publication date: October 30, 2014
    Applicant: Acucela Inc.
    Inventors: Ian L. Scott, Vladimir A. Kuksa, Mark W. Orme, Feng Hong, Thomas L. Little, Ryo Kubota
  • Publication number: 20140314857
    Abstract: In accordance with the present invention, there are provided compositions comprising zanamivir and at least one permeability enhancer. The compositions can increase the amount of zanamivir capable of being transported across a cell membrane (such as a Caco-2 cell membrane), and can increase this amount by at least 150% relative to the amount capable of being transported across the cell membrane in the absence of the permeability enhancer. Also provided are oral dosage forms of the compositions, which comprise a therapeutically effective amount of zanamivir and a permeability-enhancing amount of a permeability enhancer. The oral dosage forms can further comprise an enteric- or pH-sensitive coating or layer surrounding the composition. Also provided in accordance with the present invention are methods for treating or preventing influenza infection.
    Type: Application
    Filed: June 30, 2014
    Publication date: October 23, 2014
    Inventors: Eric Holmes, Michael Hite, Gary K. Ostrander
  • Publication number: 20140315905
    Abstract: Novel substituted benzamide based inhibitors, their use in therapy, pharmaceutical compositions comprising the compounds, the use of said compounds in the manufacture of medicaments, and therapeutic methods comprising the administration of said compounds are described. The present compounds modulate the activity of 11?-hydroxysteroid dehydrogenase type 1 (11?HSD1) and are accordingly useful in the treatment of diseases in which such a modulation is beneficial, such as the metabolic syndrome.
    Type: Application
    Filed: July 2, 2014
    Publication date: October 23, 2014
    Inventor: Soren Ebdrup
  • Publication number: 20140309208
    Abstract: Disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds are disclosed that are represented by general formula (I). Also disclosed, are pharmaceutical compositions including these compounds and methods of using these compounds and compositions for the treatment of chemokine-mediated pathologies.
    Type: Application
    Filed: October 26, 2012
    Publication date: October 16, 2014
    Inventors: Branislav Musicki, Jerôme Aubert, Jean-Guy Boiteaux, Laurence Clary, Patricia Rossio, Marlène Schuppli-Nollet
  • Patent number: 8858991
    Abstract: Disclosed herein are controlled-release oral pharmaceutical dosage forms comprising MGBG, and their application for the improved treatment of diseases with reduced side effects and/or longer time at maximum concentration.
    Type: Grant
    Filed: January 19, 2012
    Date of Patent: October 14, 2014
    Assignee: Pathologica LLC
    Inventors: John McKearn, Jeremy Blitzer
  • Patent number: 8846609
    Abstract: The present invention relates to methods for preventing or treating Human Immunodeficiency Virus (HIV) infection, inflammatory conditions, and graft-versus-host-disease (GVHD) in a subject. Therapeutic compositions of the present invention comprise Leukocidin E (LukE) and/or D proteins or polypeptides. The invention further relates to methods of treating Staphylococcus aureus infection by administering a composition comprising a CCR5 antagonist or any molecule that blocks LukE/D interaction with CCR5+ cells in an amount effective to treat the S. aureus infection in the subject.
    Type: Grant
    Filed: June 19, 2012
    Date of Patent: September 30, 2014
    Assignee: New York University
    Inventors: Victor J. Torres, Derya Unutmaz, Francis Alonzo, III
  • Patent number: 8841290
    Abstract: Disclosed is a tetrahydronapthalene compound having Formula I the variables of which are as described herein, methods of preparing same and their use.
    Type: Grant
    Filed: February 12, 2010
    Date of Patent: September 23, 2014
    Assignee: Sanofi
    Inventors: Lothar Schwink, Siegfried Stengelin, Matthias Gossel, Klaus Wirth
  • Publication number: 20140275008
    Abstract: Provide herein are compounds and pharmaceutical compositions suitable as modulators of hemoglobin, methods and intermediates for their preparation, and methods for their use in treating disorders mediated by hemoglobin and disorders that would benefit from tissue and/or cellular oxygenation.
    Type: Application
    Filed: March 15, 2013
    Publication date: September 18, 2014
    Inventors: Qing Xu, Zhe Li
  • Publication number: 20140275043
    Abstract: The present invention relates generally to compositions and methods for treating neurodegenerative diseases and disorders, particularly ophthalmic diseases and disorders. Provided herein are substituted 3-phenylpropylamine derivative compounds and pharmaceutical compositions comprising said compounds. The subject compositions are useful for treating and preventing ophthalmic diseases and disorders, including age-related macular degeneration (AMD) and Stargardt's Disease.
    Type: Application
    Filed: March 11, 2014
    Publication date: September 18, 2014
    Applicant: Acucela Inc.
    Inventors: Vladimir A. Kuksa, Mark W. Orme, Feng Hong, Ryo Kubota
  • Patent number: 8834920
    Abstract: Short oligopeptides are provide which are capable of binding to the epidermal growth factor receptor on the surface of human tumor cells. Methods for using the peptides as targeting moieties in more complex compositions, such as conjugates of cytoxins, and/or structures, such as liposomal structures, for the purposes of drug delivery are also provided.
    Type: Grant
    Filed: December 20, 2007
    Date of Patent: September 16, 2014
    Assignee: Alza Corporation
    Inventors: Ken Shi Kun Huang, Weiming Zhang, Guoyang Zhang, Francois Nicol, Anthony Huang
  • Publication number: 20140255479
    Abstract: The present invention provides pharmaceutical compositions suitable for oral and methods of treating subjects in need thereof. The pharmaceutical compositions of the present invention enhance bioavailability of at least one compound classified as BCS Class II, BCS Class III or BCS Class IV.
    Type: Application
    Filed: March 5, 2014
    Publication date: September 11, 2014
    Inventors: Stephen M. Carl, John Stanley Vrettos, William Stern